Status and phase
Conditions
Treatments
About
The patients affected by severe chronic respiratory failure can develop hypercapnic decompensation leading to coma and death in a few hours. At present, the main treatment is noninvasive or invasive ventilation. The noninvasive invasive ventilation requires a minimum of consciousness to insure spontaneous ventilation. In case of noninvasive ventilation impossibility, invasive mechanical ventilation is proposed to patients, which is an aggressive therapy. Regularly, the patients undergo this aggressive therapy without having expressed their opinion. Indeed, a great majority of these patients with severe respiratory insufficiency did not anticipate directives in case of respiratory decompensation (acceptation of aggressive treatments). Efficiency of these aggressive therapies is still uncertain but certainly alters quality of life (discomfort, loss of autonomy...). After complete, clear, loyal and adapted information, a majority of patient do not wish to go on these aggressive therapies. At the time of the decompensation, the patients are incapable to express an opinion because of the hypercapnic narcosis. An extracorporeal CO2 remover device, such as the DECAP CO2, would quickly decrease the hypercapnia what would allow the patient to improve his state of consciousness and so to find the conditions of spontaneous ventilation required for the noninvasive ventilation. The DECAP CO2 device can be used to stop quickly the hypercapnic narcosis and to collect the wills of the patient on the choice of possible aggressive therapies. It is in this last condition that we wish to estimate the DECAP CO2 device.
Full description
After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adult patient suffering from severe chronic respiratory failure
Obtaining of the consent of the patient or the reliable person or the close relation
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
32 participants in 2 patient groups
Loading...
Central trial contact
Patrick LACARIN
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal